» Articles » PMID: 17236204

Phosphocholine As a Biomarker of Breast Cancer: Molecular and Biochemical Studies

Overview
Journal Int J Cancer
Specialty Oncology
Date 2007 Jan 20
PMID 17236204
Citations 98
Authors
Affiliations
Soon will be listed here.
Abstract

The discovery of metabolic and molecular markers that help improving the detection and diagnosis of breast cancer is an important goal to be achieved. A high composite-choline signal in magnetic resonance spectra of breast lesions has been demonstrated to improve the accuracy of breast cancer diagnosis. In the present study we revealed the principal molecular and biochemical steps associated with the induction of choline metabolism and phosphocholine accumulation in human breast cancer cell-lines in comparison with normal human mammary epithelial cells. We found upregulation of the expression levels of specific choline transporters: organic cation transporter-2 and choline high affinity transporter-1, as well as of the enzyme choline kinase alpha in the cancerous cells in comparison with that in the normal mammary epithelial cells. The expression levels of choline transporter like-1, organic cation transporter-1 and choline kinase beta were similar in normal and cancerous cells. We further showed that choline transport rates and choline kinase activity indeed increased by several fold in the cancer cells leading to the elevation of phosphocholine. The results strongly suggest that phosphocholine can serve as a biomarker of breast cancer reflecting upregulation of specific choline transporters and choline kinase genes.

Citing Articles

A New Light-Sensor System Affecting Cancer Cell Fate.

Buonvino S, Arciero I, Moretti S, Iorio E, Melino S Biomater Res. 2025; 29:0157.

PMID: 40046560 PMC: 11880576. DOI: 10.34133/bmr.0157.


Metabolic Profiling of Breast Cancer Cell Lines: Unique and Shared Metabolites.

Gallo M, Ferrari E, Brugnoli F, Terrazzan A, Ancona P, Volinia S Int J Mol Sci. 2025; 26(3).

PMID: 39940737 PMC: 11816582. DOI: 10.3390/ijms26030969.


Emerging Biomarkers in Metabolomics: Advancements in Precision Health and Disease Diagnosis.

Vo D, Trinh K Int J Mol Sci. 2024; 25(23).

PMID: 39684900 PMC: 11642057. DOI: 10.3390/ijms252313190.


The Utility of [18]F-Fluorocholine Positron Emission Computed Tomography and [18]F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in Evaluating Breast Cancer Phenotypes: A Pilot Study.

Zakaria M, Shaharudin S, Ahmad Saad F Eurasian J Med. 2024; 56(2):78-85.

PMID: 39145500 PMC: 11332258. DOI: 10.5152/eurasianjmed.2024.23047.


EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis.

Glotzbach A, Rohlf K, Gonscharow A, Luke S, Demirci O, Begher-Tibbe B Breast Cancer Res. 2024; 26(1):87.

PMID: 38816770 PMC: 11138102. DOI: 10.1186/s13058-024-01849-y.